NH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | NH | Market Cap | 33,684 Cr. | Current Price | 1,648 ₹ | High / Low | 2,372 ₹ |
| Stock P/E | 68.2 | Book Value | 114 ₹ | Dividend Yield | 0.27 % | ROCE | 19.4 % |
| ROE | 21.0 % | Face Value | 10.0 ₹ | DMA 50 | 1,783 ₹ | DMA 200 | 1,779 ₹ |
| Chg in FII Hold | 0.61 % | Chg in DII Hold | 0.15 % | PAT Qtr | 109 Cr. | PAT Prev Qtr | 138 Cr. |
| RSI | 35.0 | MACD | -41.9 | Volume | 2,71,909 | Avg Vol 1Wk | 3,41,874 |
| Low price | 1,380 ₹ | High price | 2,372 ₹ | PEG Ratio | 1.47 | Debt to equity | 0.69 |
| 52w Index | 27.0 % | Qtr Profit Var | 37.1 % | EPS | 22.6 ₹ | Industry PE | 43.5 |
📊 Narayana Hrudayalaya (NH) shows strong profitability metrics with ROE (21.0%) and ROCE (19.4%), but valuations are stretched with a P/E of 68.2 compared to industry average of 43.5. The PEG ratio of 1.47 suggests moderate growth relative to valuation. Dividend yield is low at 0.27%, offering limited income support. Technical indicators (RSI 35.0, MACD -41.9) show weakness, with the stock trading below both 50 DMA (1,783 ₹) and 200 DMA (1,779 ₹). The ideal entry zone for long-term investors would be ₹1,450–₹1,550, closer to its recent low of ₹1,380. If already holding, investors should maintain a 3–5 year horizon, with partial exits near ₹2,200–₹2,350 to capture gains.
✅ Positive
- Strong ROE (21.0%) and ROCE (19.4%) highlight efficient capital use.
- EPS of ₹22.6 reflects solid earnings power.
- FII holding increased (+0.61%), showing foreign investor confidence.
- 52-week return of 27% shows resilience despite volatility.
⚠️ Limitation
- High P/E (68.2) compared to industry average (43.5).
- Dividend yield of 0.27% is very low.
- Debt-to-equity ratio of 0.69 indicates moderate leverage.
- Stock trading below key moving averages (DMA 50 & DMA 200).
📉 Company Negative News
- Quarterly PAT declined from ₹138 Cr. to ₹109 Cr.
- Technical weakness: RSI near oversold zone (35.0), MACD negative (-41.9).
📈 Company Positive News
- DII holding increased (+0.15%), showing domestic institutional support.
- Quarterly profit variation (+37.1%) indicates earnings recovery momentum.
- Market cap of ₹33,684 Cr. reflects strong industry presence.
🏭 Industry
- Industry P/E at 43.5 suggests peers trade at lower valuations.
- Healthcare sector expected to benefit from rising demand for quality medical services and hospital expansion.
🔎 Conclusion
NH is a fundamentally strong healthcare company with high efficiency metrics and growing investor confidence. However, valuations are stretched, and dividend yield is low. Long-term investors can accumulate in the ₹1,450–₹1,550 zone for better risk-reward. Existing holders should maintain a 3–5 year horizon, with partial exits near ₹2,200–₹2,350. Strong ROE and sector tailwinds support long-term growth, but valuation risks and near-term technical weakness warrant cautious positioning.